logo
How £120 airline luggage fees spiralled out of control

How £120 airline luggage fees spiralled out of control

Telegrapha day ago

Have airline luggage fees gone too far? While anyone who's been within a mile of Stansted knows that budget airlines have steep baggage charges, the speed with which those fees have been escalating across Europe in recent years has been enough to give even experienced travellers a nasty surprise.
At least that's the view of the European Commission, which is proposing new legislation to get the likes of Ryanair, easyJet and Wizz Air to standardise their baggage rules. The move is being cheered on by consumer rights groups who have spent years complaining that airline luggage fees are unfair.
It's true that the red-tape enthusiasts in Brussels aren't known for their intelligent, pro-market approach. But on the other hand, there's no denying that the airlines have been taking liberties when it comes to their baggage charges – many of which have spiked several times since the pandemic.
Look at Ryanair, which has tweaked at least one of its baggage charges every year for the past four summers. The end result is that the maximum charge for storing a 10kg suitcase has gone from £23.99 to £44.99 – an 88 per cent jump – and the maximum fee for a 20kg checked bag has risen from £39.99 to £59.99. Meanwhile, bringing a larger bag for hand luggage could cost you as much as £36 (up from £20 just four years ago). Given that the fees are per flight, you'll need to double those numbers if you want to bring the bag back with you.
Because of how Ryanair's fees work – with the exact cost depending on the flight in question – it isn't easy to make a like-for-like comparison. But a quick search of some of the most popular routes this summer confirms that passengers are almost certainly paying more than they were before the pandemic.
Looking at a flight from Stansted to Santorini on June 27, for example, a 10kg check-in bag will cost £28.99 one-way. But we can see from archived versions of Ryanair's website that the maximum fee for that service was £23.99 until just three years ago – so there's absolutely no way someone would be paying that much.
Like the proverbial boiling frog, these bigger changes have happened bit by bit. In 2023, a 10kg bag was capped at £25 each way; in 2024, it increased to £29.99; this year, it jumped all the way to £44.99. In other words, if you've been thinking that your summer jaunt to Turkey has been going up in price in recent years, it probably isn't in your imagination.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wood Group takeover talks extended again amid regulatory probe
Wood Group takeover talks extended again amid regulatory probe

Daily Mail​

time27 minutes ago

  • Daily Mail​

Wood Group takeover talks extended again amid regulatory probe

John Wood Group has again extended the deadline for suitor Sidara to make a concrete takeover offer for the company. It follows the launch of a City watchdog investigation into Wood Group last week after an independent review unearthed 'cultural failings' with its accounting practices. The North Sea-focused oilfield services provider told investors on Monday Dubai-based Sidara now has until 5pm on 28 July to put forward a 'put up or shut up' proposal, having originally given the firm until today to do so. Sidara began a fresh move for Wood Group in February after a previous attempt to acquire the company in a £1.7billion deal last year failed. However, Wood Group refused to accept the offer after two months of talks, blaming 'rising geopolitical risks and financial market uncertainty'. Sidara eventually put forward a far lower 35p per share bid in April, which values Wood Group at around £240million. The offer additionally includes a potential $450million capital injection and Wood Group possibly pursuing an extension or amendment to its current debt facilities. Wood Group shares have plummeted by approximately 84 per cent over the past year amidst cash flow problems, massive contract write-offs and accounting failures. In February, the Edinburgh-based firm warned that it expected between $150million and $200million in negative free cash flow this year owing to subdued trading and legacy claims liabilities totalling about $150million. Its chief financial officer, Arvind Balan, resigned soon afterwards when he admitted to inaccurately describing his professional qualifications. A month later, Wood Group admitted that its previous financial statement would have to be restated after a Deloitte probe uncovered 'material weaknesses and failures' in the financial culture of its projects business. Following delays in publishing its 2024 results, the company's shares were suspended from trading on the London Stock Exchange in April. And just last week, the Financial Conduct Authority (FCA) began its own investigation into Wood Group, which will look at the firm's conduct between January 2023 and November 2024. Founded as Dar al-Handasah in Lebanon in 1956, Sidara is a network of engineering and design companies employing about 21,500 people with a specialist focus on large-scale building projects. Wood Group employs 35,000 individuals across more than 60 countries who give consultation, engineering, and management services to the energy and minerals sectors. Private equity giant Apollo Global Management tried to purchase Wood Group in 2023, making four proposals, including a final offer of 240p per share, before the latter walked away without explanation.

UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers
UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers

Daily Mail​

time35 minutes ago

  • Daily Mail​

UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers

Medicines firm Hikma Pharmaceuticals plans to invest $1billion into US manufacturing and research and development over the next five years. The London-headquartered firm told investors on Monday the investment would expand its domestic capabilities 'to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide'. Hikma specialises in generic medicines - medications created to be the same as a brand-name drug, but usually sold at a lower cost. It comes as the UK-US trade deal comes into effect today, leaving UK carmakers with reduced tariffs of 10 per cent and removing levies on the aerospace sector entirely. However, Britain's pharmaceutical sector still faces the potential for further tariffs down the line, as well as recent suggestions the White House could move to clamp-down on the price of medicines in the US. UK pharma sold £6.6billion worth of products to the US last year, meaning the sector is Britain's second-biggest export to the country. President Donald Trump's threat to end exemptions on pharma tariffs, which are driven by a 1995 World Trade Organisation deal, has sparked fears that disruption to the sector's highly complex supply chain could have implications for UK pharmacies and patients. Hikma said on Monday it has provided access 'to a wide range of generic medicines at a lower cost than branded products' since operating in the US since 1991. The group's 'America Leans on Hikma' strategy plans to increase the volume of 'essential medicines' developed and produced across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and New Jersey. Hikma said: 'This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.' President of Hikma's generics business Dr. Hafrun Fridriksdottir added: 'We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients. 'Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store